A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. - Wikidata - awgldk - TriplyDB

A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma.

A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma.

http://www.wikidata.org/entity/Q36381565

about

Treatment of relapsed and refractory multiple myeloma Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives From clinical trials to clinical practice: single-agent carfilzomib adverse events and their management in patients with relapsed and/or refractory multiple myeloma NF-kappa B modulation is involved in celastrol induced human multiple myeloma cell apoptosis The role of SLAMF7 in multiple myeloma: impact on therapy.Efficacy of single-agent bortezomib vs. single-agent thalidomide in patients with relapsed or refractory multiple myeloma: a systematic comparison.Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation.Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma.Peripheral neuropathy outcomes and efficacy of subcutaneous bortezomib when combined with thalidomide and dexamethasone in the treatment of multiple myeloma.5-hydroxy-2-methyl-1,4-naphthoquinone, a vitamin K3 analogue, suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase, SHP-1: potential role in chemosensitization.Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations.Betulinic acid suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase SHP-1 in human multiple myeloma cells.Access to thalidomide for the treatment of multiple myeloma in Canada: physician behaviours and ethical implications.Immunomodulatory drugs in multiple myeloma.Thymoquinone inhibits proliferation, induces apoptosis and chemosensitizes human multiple myeloma cells through suppression of signal transducer and activator of transcription 3 activation pathway Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs.The use of novel agents in the treatment of relapsed and refractory multiple myeloma Dihydroxypentamethoxyflavone down-regulates constitutive and inducible signal transducers and activators of transcription-3 through the induction of tyrosine phosphatase SHP-1 Celastrol inhibits proliferation and induces chemosensitization through down-regulation of NF-κB and STAT3 regulated gene products in multiple myeloma cells.Treatment with Thalidomide and Cyclophosphamide (TCID) is Superior to Vincristine (VID) and to Vinorelbine (VRID) Regimens in Patients with Refractory or Recurrent Multiple Myeloma.Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial.Bendamustine in patients with relapsed or refractory multiple myeloma.Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development.Thalidomide in multiple myeloma: past, present and future.New horizons in multiple myeloma therapy.Current status of new drugs for the treatment of patients with multiple myeloma.From the bench to the bedside: emerging new treatments in multiple myeloma.Current trends in multiple myeloma management.Treatment of relapsed and refractory myeloma.A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma Role of thalidomide in previously untreated patients with multiple myeloma.Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma.Efficacy and toxicity of the combination chemotherapy of thalidomide, alkylating agent, and steroid for relapsed/refractory myeloma patients: a report from the Korean Multiple Myeloma Working Party (KMMWP) retrospective study.Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature.Long-Term Effects, Pathophysiological Mechanisms, and Risk Factors of Chemotherapy-Induced Peripheral Neuropathies: A Comprehensive Literature Review.Cost-effectiveness of lenalidomide in multiple myeloma.Development of target-specific treatments in multiple myeloma.The Belgian 2010 consensus recommendations for the treatment of multiple myeloma.

P2860

Q26749180-2F1F7070-02D5-4499-AA71-A4683D677072 Q26771331-C78E6E9B-FF2B-41D9-84A9-69610621D765 Q26799104-927BA92B-73D8-4198-B9EA-0A8B944E2BE7 Q26862828-5BACD03F-EB0E-4934-A04E-3144962245CA Q28538133-E85DCE47-8533-437F-920A-A8DEFE672E1B Q30249167-CC422451-8DF5-4FEC-AE2D-F2D593250DBD Q33289791-097FF415-4375-497A-9C0B-542DFEF38F72 Q33322921-218CBA6F-970B-475D-9C25-03C3F6B146CD Q33389075-4AA0C13F-AC6B-4605-9F85-4B3A0BFA6243 Q33437045-0528B4CB-B64D-4167-9820-2A55230AF266 Q33598740-7CD214D5-CDFF-4EF2-9AAF-00BC7AA26950 Q33632270-5F344950-6500-4EA2-AE65-392175383BAA Q33879341-72CDFBB3-1557-40C2-BE18-AA309D60B5B9 Q34035424-6FA440A2-64F2-4405-BCA5-9709EFE4FAA6 Q34325722-2BD83C80-78A2-4286-B2FE-AA3516E6ED34 Q34342251-52B1C9B4-3D4C-46C9-847F-A80A94201FC1 Q34571555-A5D99016-3F95-44C3-8EF9-E3C6ECB9015E Q35097319-01F502C5-A828-4B00-9DF7-CFDDE6839646 Q35415906-0DE3DB49-ADC8-4838-8F30-3BE8024C22A9 Q35564293-79D42270-8044-4A6F-B947-AE3E6936C8DA Q35904262-A055135E-AEE0-4F2B-B6DB-2369C21A4386 Q35930659-EB71E446-9EBD-498C-B6C8-9D64E9ED7A44 Q35958553-DC0A9242-4127-4CD5-8BFA-EE5BAF2782A6 Q36382493-81B9E741-90DD-4DA4-BD65-76A83B949EC4 Q36612613-20F700AF-6CBA-4932-A074-52E028FBB1A1 Q36616493-352DCCDC-49D5-455A-B05E-1085F0854704 Q36636660-E3C22B96-F15A-430E-8BD2-9A7B1789C7A7 Q36649839-967EB749-761D-4443-93A1-E6559E037DC0 Q37028598-4D6F7D78-E49C-4BD2-BD1D-F694FA64937F Q37183557-B5E8A582-2A82-4BE5-8C67-70F08C0A448B Q37209929-BD7E0771-CDFE-43ED-AAB5-7BD6936FF012 Q37219701-F8B35111-5777-4C5D-9DBE-45D686CEC184 Q37300004-0A3BB227-B963-4A25-A01F-D0D9B94A6EE2 Q37310407-378582BD-D5D8-4AD4-B62A-EE28403BE19C Q37609489-39976286-995C-47D5-B7CB-12E04DFA3D03 Q37659699-6401784C-2494-4C33-A5D3-AC0A34D89101 Q37662576-28D859C0-722E-4792-BF48-FBCE1A105882 Q37764870-B1F441A4-60A9-44D6-AA74-9446622DA5B0 Q37771370-216A667F-BE0B-407C-9E39-29CEBB73B093 Q37800884-7907F35C-CDBE-4F8E-8322-2C61D1F60F8D

P2860

A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma.

http://www.wikidata.org/entity/Q36381565

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh

2006年學術文章

@zh-hant

name

A systematic review of phase-I ...... r refractory multiple myeloma.

@ast

A systematic review of phase-I ...... r refractory multiple myeloma.

@en

type

label

A systematic review of phase-I ...... r refractory multiple myeloma.

@ast

A systematic review of phase-I ...... r refractory multiple myeloma.

@en

prefLabel

A systematic review of phase-I ...... r refractory multiple myeloma.

@ast

A systematic review of phase-I ...... r refractory multiple myeloma.

@en

P1433

Q36381565-1A36B34C-158A-410F-86F8-D2EC3C8AA6A7

P1476

Q36381565-549303AC-3162-4D36-B18D-E2EEAA8BA59C

P2093

Q36381565-16259311-3A1F-4D45-8132-B22A9F099B6A

Q36381565-17E7329F-3AA2-4D34-BC30-BD93B9B3D5CE

Q36381565-2BD511E0-8323-4B8F-BAEA-3E8B553B9D7D

Q36381565-750C8C05-3130-49D9-8C83-952E9CACCF69

Q36381565-85B89CB3-5782-4B08-A90E-FD1C59C7629B

Q36381565-9A0C49D8-9D29-4A92-8B48-9778C9BB981D

Q36381565-C0D87083-3B98-40DC-AC4D-D872E93F00FA

Q36381565-F1BB14C7-3017-4EC9-AEE3-AB6606D7D942

P2860

Q36381565-014C1583-F0A4-4241-80A2-CF6DB9B24E52

Q36381565-09910DCD-2796-404B-A532-27EF1EAB590D

Q36381565-1169A170-F9F0-44F9-995D-DD69943DF11C

Q36381565-12835AE6-DDC4-422E-89C4-FCA26E1427BD

Q36381565-19289917-2F9F-4AA6-A6F6-D682A9FBA86E

Q36381565-1A562E6B-3AA4-4401-8180-2AC3E7BF68E7

Q36381565-1B4522CC-8236-4CC6-AEB1-70E9C6C88BCE

Q36381565-390ECD94-D4CB-4DF9-8419-77D58E09570C

Q36381565-3DCD9FBD-14D5-493D-8233-5ABC28D9AC87

Q36381565-3EBE2A05-8882-455A-A695-F84C84779D5B

P304

Q36381565-DBAC0AFA-1B5A-4E45-B409-56224305E245

P31

Q36381565-F7F43133-B219-4FD7-A261-B2D30542E786

P356

Q36381565-C1AD136C-D99E-4F96-82FB-640B4CDC8119

P407

Q36381565-0CCED9AB-3570-46CE-8B18-A132C8C94211

P433

Q36381565-CAD453B4-2654-40FF-875C-6F3768916D8C

P478

Q36381565-AC40A989-7E48-43E2-A19B-E35DD0EBF057

P50

Q36381565-AD4AB93E-931B-4CFB-B3E4-20E8F8C770F1

P577

Q36381565-116612FA-1800-475A-8A26-F8285EA27C6D

P5875

Q36381565-D7820F7C-D9E5-42D2-B52C-AC164946295B

P698

Q36381565-FAFC5406-1BE9-47C9-8A1F-965659FE5452

P921

Q36381565-0722DFDD-95FE-4BC5-A1C2-6D3DC66868C5

Q36381565-397D1902-EE4E-497C-9613-1E39ACA9AC33

P356

J.1365-2141.2005.05914.X

P1433

British Journal of Haematology

P1476

A systematic review of phase-I ...... r refractory multiple myeloma.

@en

P2093

Axel Glasmacher

http://www.w3.org/2001/XMLSchema#string

Corinna Hahn

http://www.w3.org/2001/XMLSchema#string

Florian Hoffmann

http://www.w3.org/2001/XMLSchema#string

Ingo Schmidt-Wolf

http://www.w3.org/2001/XMLSchema#string

Katjana Orlopp

http://www.w3.org/2001/XMLSchema#string

Marcus Gorschlüter

http://www.w3.org/2001/XMLSchema#string

Marie von Lilienfeld-Toal

http://www.w3.org/2001/XMLSchema#string

Ralph Naumann

http://www.w3.org/2001/XMLSchema#string

P2860

Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study.

Antitumor activity of thalidomide in refractory multiple myeloma.

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant.

The blood coagulation mechanism in multiple myeloma.

Intermediate dose thalidomide (200 mg daily) has comparable efficacy and less toxicity than higher doses in relapsed multiple myeloma.

Treatment of plasma cell dyscrasias with thalidomide and its derivatives.

Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma.

The current status of thalidomide in the management of multiple myeloma.

Thalidomide in multiple myeloma: current status and future prospects.

Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma.

P304

584-593

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2141.2005.05914.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

132

http://www.w3.org/2001/XMLSchema#string

P50

Hartmut Goldschmidt

P577

2006-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7327760

http://www.w3.org/2001/XMLSchema#string

P698

16445831

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial